Lv7
3310 积分 2024-03-16 加入
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA
9天前
已完结
Cost-effectiveness analysis of sintilimab+chemotherapy versus camrelizumab+chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China
1个月前
已完结
A Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases
1个月前
已完结
The order of entry effect in prescription (Rx) and over‐the‐counter (OTC) pharmaceutical drugs
2个月前
已完结
Size and dynamics of order-of-entry effects in pharmaceutical markets
2个月前
已完结
Mitochondrial Unfolded Protein Response (mtUPR) and Diseases
3个月前
已完结
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
4个月前
已完结
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
5个月前
已完结
Coste-efectividad de la utilización de la tirotropina recombinante humana previa a la ablación con radioyodo en el tratamiento del cáncer de tiroides en hospitales españoles
9个月前
已完结
皖公网安备34019202002308
